Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy
作者:Zigao Yuan、Shaopeng Chen、Chunmei Gao、Qiuzi Dai、Cunlong Zhang、Qinsheng Sun、Jin-Shun Lin、Chun Guo、Yuzong Chen、Yuyang Jiang
DOI:10.1016/j.bioorg.2019.03.027
日期:2019.6
enzymatic inhibitory potency needs to be improved. Herein we reported the development of a novel dual DNMT and HDAC inhibitor C02S which showed potent enzymatic inhibitory activities against DNMT1, DNMT3A, DNMT3B and HDAC1 with IC50 values of 2.05, 0.93, 1.32, and 4.16 µM, respectively. Further evaluations indicated that C02S could inhibit DNMT and HDAC at cellular levels, thereby inversing mutated methylation
DNMT和HDAC彼此密切相关,并涉及各种人类疾病,尤其是癌症。这两种酶已被广泛认为是药物发现的抗肿瘤靶标。此外,研究表明由DNMT和HDAC抑制剂组成的联合疗法具有治疗优势。我们已经报告了DNMT和HDAC双重抑制剂15a,其中DNMT的酶促抑制效能需要提高。本文中,我们报道了新型DNMT和HDAC双重抑制剂CO2S的开发,该抑制剂显示出对DNMT1,DNMT3A,DNMT3B和HDAC1的有效酶抑制活性,IC 50值分别为2.05、0.93、1.32和4.16 µM。进一步评估表明,CO2S可以在细胞水平上抑制DNMT和HDAC,从而逆转突变的甲基化和乙酰化并增加肿瘤抑制蛋白的表达。此外,CO 2 S调节多种生物学过程,包括诱导凋亡和G0 / G1细胞周期停滞,抑制血管生成,阻断迁移和侵袭,并最终抑制体外肿瘤细胞增殖和体内肿瘤生长。